Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability, PK, and Food Effect of Milvexian Formulations
NCT04844424Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of milvexian in thromboembolism, ischemic stroke, acute coronary syndrome (ACS) and 1 more (9 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Area Under the Plasma Concentration-time Curve up to 16 months, Maximum Observed Analyte Concentration up to 16 months and 1 more. Started Apr 2021; status: completed.
02
Drugs
milvexian
03
Conditions
thromboembolismischemic strokeacute coronary syndrome (ACS)venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT04844424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04844424.